人类葡萄糖受体对Gs和Gi的识别的结构基础
概括
结构研究揭示了人类葡萄糖受体 (GCGR) 如何与不同的G蛋白结合. 受体细胞内环中的关键差异决定了Gs或Gi1蛋白结合的选择性.
科学领域:
- 生物化学
- 结构生物学
- 药理学
背景情况:
- 乙类G蛋白结合受体 (GPCR) 是关键的治疗点.
- 这些受体主要通过Gs异构G蛋白发出信号,但表现出结合性.
- 了解传感器的作用对于药物开发至关重要.
研究的目的:
- 阐明人类葡萄糖受体 (GCGR) 的G蛋白结合选择性的结构基础.
- 调查 GCGR 与 Gs 和 Gi1 G 蛋白质的不同相互作用.
主要方法:
- 使用冷电子显微镜 (cryo-EM) 来确定高分辨率结构.
- 使用突变和功能测试来验证结构发现.
主要成果:
- 通过Gs或Gi1来结合GCGR的两个不同的结构得到了解决.
- Gs和Gi1都在类似的开放腔内结合,但选择性是由特定的相互作用驱动的.
- 在受体的细胞内环形变异被确定为G蛋白选择性的关键决定因素.
- 较大的相互作用接口有利于Gs结合,而特定的相互作用则影响Gi结合.
结论:
- 这项研究为GCGR的G蛋白结合选择性提供了原子层面的见解.
- 细胞内环形状是决定传感器参与的关键因素.
- 这些发现为设计GCGR信号的选择性调制器提供了结构基础.
相关概念视频
Transducer Mechanism: G Protein–Coupled Receptors
3.6K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
3.6K
GPCRs Regulate Adenylyl Cylase Activity
7.0K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.0K
G Protein-coupled Receptors
16.1K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.1K
Activation and Inactivation of G Proteins
10.4K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
10.4K
Insulin: The Receptor and Signaling Pathways
2.4K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.4K
Glucagon-like Receptor Agonists
757
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
757


